OlgaFrankfurtMD
Hematology • Chicago, ILAssistant Professor in Medicine-Hematology/Oncology, Northwestern University Medical School
Dr. Frankfurt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
675 N Saint Clair St
Suite 21-100
Chicago, IL 60611Phone+1 312-695-0990- Is this information wrong?
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
Rush University Medical CenterResidency, Internal Medicine, 1999 - 2002
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1999
Certifications & Licensure
IL State Medical License 2002 - 2026
FL State Medical License 2022 - 2026
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2007 Nov 15
- Join now to see all
Publications & Presentations
PubMed
- Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.Altman, J., Zuckerman, T., Koprivnikar, J., McCloskey, J., Kota, V., Keng, M., Frankfurt, O., Abaza, Y., Bixby, D., Emadi, A., Burch, M., Bhatnagar, B., Luger, S., Per...> ;Blood Advances. 2023 Dec 26
- 24 citationsEnasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.Stéphane de Botton, Pau Montesinos, Andre C Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A Larson, Jaime ...> ;Blood. 2023 Jan 12
- Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.Shuo Ma, Steven T Rosen, Maria Winqvist, Olga Frankfurt, Jane N Winter, Leo Gordon, Irene Helenowski, Hui Zhang, Jennifer Kreutzer, Sonja Sönnert-Husa, Anders Österbor...> ;Leukemia Research. 2022 Nov 1
- Join now to see all
Journal Articles
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
Abstracts/Posters
- Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integr...Olga Frankfurt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...Olga Frankfurt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Apellis Announces U.S. FDA Approval of Empaveli (Pegcetacoplan) for Adults with Paroxysmal Nocturnal HemoglobinuriaMay 20th, 2021- Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)May 14th, 2021
Midday Fix: Campaign 2 Save Lives – Event to Help Those Battling LeukemiaMay 15th, 2018- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Northwestern Memorial HospitalChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
